Press Releases

• Pertuzumab Plus Trastuzumab and Docetaxel Will Become Decision Resources’ Proprietary Clinical Gold-Standard Treatment for Metastatic First-Line HER2-Positive Breast Cancer in 2015
  February 2, 2012
  The Breast Cancer Drug Market Will Increase from $9.3 Billion in 2011 to $10.8 Billion in 2020, According to Findings from Decision Resources
  Read More
• Surveyed U.S. Endocrinologists Indicate They Would Prescribe Amylin/Alkermes’ Bydureon to 20 Percent of Their Patients With Type 2 Diabetes
  February 1, 2012
  Bydureon Will Earn Decision Resources’ Proprietary Clinical Gold-Standard Status for Type 2 Diabetes in 2015, According to Findings from Decision Resources
  Read More
• Surveyed U.S. Cardiologists Indicate That They Would Prescribe Cardiome/Merck’s Oral Vernakalant and Gilead/Menarini’s Ranolazine to 13 Percent of Their Atrial Fibrillation Patients
  February 1, 2012
  The Atrial Fibrillation Drug Market Will Undergo Significant Growth, Expanding from $1.3 Billion in 2010 to $8.9 Billion in 2020, According to Findings from Decision Resources
  Read More
• Surveyed U.S. Psychiatrists Indicate They Would Prescribe Forest Laboratories/Pierre Fabre’s Levomilnacipran to 25 Percent of Their Patients with Treatment-Resistant Depression
  January 30, 2012
  In 2020, Levomilnacipran Will Garner a Patient Share of Approximately 5 Percent of the Drug Treated Unipolar Depression Population in the U.S., According to Findings from Decision Resources
  Read More
• Decision Resources Group to Bring its One-Day Oncology Seminar to San Francisco
  January 23, 2012
  Geared Toward Pharmaceutical and Biotech Executives, This One-Day Event Will Address Oncology Drug Market Drivers, Challenges and Opportunities
  Read More
• Surveyed EU5 Rheumatologists Estimate that About One Quarter of Their TNF-Alpha Inhibitor-Treated Patients with Psoriatic Arthritis, Ankylosing Spondylitis or Undifferentiated Spondyloarthritis Demonstrate an Inadequate Response to These Agents
  December 21, 2011
  Interviewed European Payers Say Emerging Drugs with Novel Mechanisms of Action May Struggle to Be Used as First-Line Biologics in Some EU5 countries, According to a New Report from Decision Resources
  Read More
• Linaclotide Will Become the New Market Leader and Achieve Blockbuster Status By 2018 for the Treatment of Irritable Bowel Syndrome
  December 21, 2011
  Thought Leaders and Regulators Have Reservations About the Use of Antibiotics in Treating IBS, According to Findings from Decision Resources
  Read More
• Through 2020, Rib-X’s Radezolid Will Be the Only Agent to Launch for Community-Acquired Bacterial Pneumonia
  December 21, 2011
  The Demonstration of Safety Advantages over Pfizer’s Zyvox Will Be a Key Factor in Radezolid’s Ability to Take Significant Market Share From Zyvox, According to Findings from Decision Resources
  Read More
• The Ulcerative Colitis Drug Market Will Increase from $1.7 Billion in 2010 to $3 Billion in 2020 as New Agents Will Offer Additional Lines of Therapy for Moderate to Severe Disease
  December 19, 2011
  Key Drivers of Market Growth Will Include the Uptake of Humira, Simponi, Vedolizumab and Tofacitinib, According to Findings from Decision Resources
  Read More
• The Diabetic Retinopathy Drug Market Will Expand Nearly Eight-Fold to $700 Million by 2020
  December 19, 2011
  Vascular Endothelial Growth Factor Inhibitors Will Experience Increasing Use in Diabetic Retinopathy Patients Who Also Have Diabetic Macular Edema, According to Findings from Decision Resources
  Read More
Displaying results 1-10 (of 626)
 |<  < 1 2 3 4 5 6 7 8 9 10  >  >|